Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | GLSI | Stock Options | Award | $0 | +1.05M | $0.00 | 1.05M | Jun 22, 2022 | Common Stock | 1.05M | $7.63 | Direct | F1 | |
transaction | GLSI | Stock Options | Award | $0 | +25K | +2.38% | $0.00 | 1.07M | Jun 22, 2022 | Common Stock | 25K | $7.63 | By Wife | F2 |
Id | Content |
---|---|
F1 | The options vest over time and pursuant to milestones. 21,848 of the options vest each month for 48 months contingent on the Company meeting certain performance milestones. The Reporting Person is eligible to exercise (i) 20% of the vested options after $10 million is raised by the Company (ii) 20% after the first site is activated for the Phase 3 clinical trial, (iii) 40% after completion of interim analysis of the Phase 3 clinical trial and (iv) 20% upon filing of Biologic License Application with the US Food and Drug Administration. |
F2 | 521 options vest each month for 48 months. |